Latest & greatest articles for insomnia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insomnia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insomnia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insomnia

21. Management of Surgical Patients with Sleep Apnea: Guidelines

Management of Surgical Patients with Sleep Apnea: Guidelines Management of Surgical Patients with Sleep Apnea: Guidelines | CADTH.ca Find the information you need Management of Surgical Patients with Sleep Apnea: Guidelines Management of Surgical Patients with Sleep Apnea: Guidelines Last updated: July 29, 2019 Project Number: RB1369-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What are the evidence-based guidelines (...) for preoperative management of surgical patients with known or suspected sleep apnea? What are the evidence-based guidelines for post-operative monitoring and management of surgical patients with known or suspected sleep apnea? Key Message Two evidence-based guidelines were identified regarding preoperative management of surgical patients with known or suspected sleep apnea while no relevant guidelines were identified regarding post-operative management of surgical patients with suspected or known sleep apnea

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

22. Benzodiazepines for the Treatment of Adults with Mental Health Conditions or Sleep Disorders Guidelines

Benzodiazepines for the Treatment of Adults with Mental Health Conditions or Sleep Disorders Guidelines Benzodiazepines for the Treatment of Adults with Mental Health Conditions or Sleep Disorders Guidelines | CADTH.ca Find the information you need Benzodiazepines for the Treatment of Adults with Mental Health Conditions or Sleep Disorders Guidelines Benzodiazepines for the Treatment of Adults with Mental Health Conditions or Sleep Disorders Guidelines Last updated: August 27, 2019 Project (...) Number: RB1375-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What are the evidence-based guidelines regarding the use of benzodiazepines and benzodiazepine-related drugs for the treatment of adults with mental health conditions or sleep disorders? Key Message Nine evidence-based guidelines were identified regarding the use of benzodiazepines and benzodiazepine-related drugs for the treatment of adults with mental health conditions or sleep

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

23. The role of CPAP treatment in elderly patients with moderate obstructive sleep apnoea: a multicentre randomised controlled trial (Abstract)

The role of CPAP treatment in elderly patients with moderate obstructive sleep apnoea: a multicentre randomised controlled trial The efficacy of continuous positive airway pressure (CPAP) treatment in elderly patients with nonsevere obstructive sleep apnoea (OSA) is controversial. The objective of this study was to assess the effect of CPAP treatment in elderly patients with moderate OSA in terms of clinical, quality-of-life and neurocognitive measures.This was an open-label, randomised (...) , multicentre clinical trial in 145 elderly patients (≥70 years old) with confirmed moderate OSA (apnoea-hypopnoea index 15-29.9 events·h-1) randomised to receive CPAP (n=73) or no CPAP (n=72) for 3 months. The primary end-point was the Epworth Sleepiness Scale (ESS) score, and the secondary end-points included quality of life (Quebec Sleep Questionnaire (QSQ) domain scores), sleep-related symptoms, presence of anxiety/depression, office-based blood pressure measurements and some neurocognitive tests

2019 EvidenceUpdates

24. Melatonin (Slenyto) - Treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome

as follows: ADVICE: following a full submission melatonin prolonged-release (Slenyto ® ) is not recommended for use within NHSScotland. Indication under review: Treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient. Melatonin prolonged-release (Slenyto ® ), compared with placebo, increased total sleep time and sleep onset latency in children aged 2 to 17.5 years with sleep (...) problems and autism spectrum disorder and / or Smith-Magenis syndrome who had an insufficient response to sleep hygiene measures. The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC. Chairman Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication Treatment of insomnia in children and adolescents aged

2019 Scottish Medicines Consortium

25. SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea

syndrome or Treacher-Collins syndrome, and patients with Down's syndrome are more likely to have obstructive sleep apnoea. There are certain genetic disorders that predispose to obesity, for example Prader-Willi syndrome. Patients with certain congenital conditions may be considered to have a disability. Clinical and technical e Clinical and technical evidence vidence A literature search was carried out for this briefing in accordance with the interim process and methods statement. This briefing (...) SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea SuperNO2V SuperNO2VA for the relief of upper airwa A for the relief of upper airway y obstruction in people with obstructiv obstruction in people with obstructive sleep e sleep apnoea apnoea Medtech innovation briefing Published: 9 September 2019 www.nice.org.uk/guidance/mib190 pathways Summary Summary The technology technology described in this briefing is SuperNO2VA. It is used for preventing

2019 National Institute for Health and Clinical Excellence - Advice

26. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update

to daytime impairment. Preliminary questions for eliminating other sleep disorders as primary diagnosis are summarized below. Eliminating other sleep disorder as primary: preliminary questions – see Appendix for more detailed follow-up questions. ? Are you a very heavy snorer? Does your partner say that you sometimes stop breathing at night? (obstructive sleep apnoea syndrome (OSAS)) ? Do your legs often twitch and can’t keep still in bed? Do you wake from sleep with jerky leg movements? (restless legs (...) of epidemiological evidence suggests that insomnia typically predates other psy- chiatric symptoms and may represent an independent risk factor for the development of depression in particular (see below). Circadian rhythm disorder Circadian rhythm disorders are sleep disorders where there is a mismatch between circadian rhythms and required sleepwake cycle. Thus there can be sleeplessness when trying to sleep at a time not signalled by the internal clock, and exces- sive sleepiness when needing to be awake

2019 British Association for Psychopharmacology

27. Early Intensive Neurorehabilitation of adults with unresponsive wakefulness syndrome or a prolonged minimally conscious state

Early Intensive Neurorehabilitation of adults with unresponsive wakefulness syndrome or a prolonged minimally conscious state Early Intensive Neurorehabilitation of adults with unresponsive wakefulness syndrome or a prolonged minimally conscious state | Report | National Health Care Institute You are here: Early Intensive Neurorehabilitation of adults with unresponsive wakefulness syndrome or a prolonged minimally conscious state Search within English part of National Health Care Institute (...) Search Early Intensive Neurorehabilitation of adults with unresponsive wakefulness syndrome or a prolonged minimally conscious state Share this page Service About this site

2019 National Health Care Institute (Zorginstituut Nederland)

28. Nurse-led cognitive behavioural group treatment intervention for insomnia successfully reduces daytime symptomatology. (Abstract)

of Nursing, The University of Toronto, Toronto, Ontario, Canada. eng Journal Article Comment 2019 05 30 England Evid Based Nurs 9815947 1367-6539 IM N Int J Nurs Stud. 2018 Sep;85:126-135 29886347 Cognition Cognitive Behavioral Therapy Humans Primary Health Care Sleep Initiation and Maintenance Disorders nursing primary care Competing interests: None declared. 2019 01 29 2019 5 31 6 0 2019 6 27 6 0 2019 6 1 6 0 ppublish 31147344 ebnurs-2018-102975 10.1136/ebnurs-2018-102975 (...) Nurse-led cognitive behavioural group treatment intervention for insomnia successfully reduces daytime symptomatology. 31147344 2019 06 26 2019 06 26 1468-9618 22 3 2019 07 Evidence-based nursing Evid Based Nurs Nurse-led cognitive behavioural group treatment intervention for insomnia successfully reduces daytime symptomatology. 79 10.1136/ebnurs-2018-102975 Scott Lauren L 0000-0001-9526-2385 Faculty of Nursing, The University of Toronto, Toronto, Ontario, Canada. Bawden Jessica J Faculty

2019 Evidence-Based Nursing Controlled trial quality: uncertain

29. The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial (Abstract)

The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial Rationale: There is currently no effective pharmacological treatment for obstructive sleep apnea (OSA). Recent investigations indicate that drugs with noradrenergic and antimuscarinic effects improve genioglossus muscle activity and upper airway patency during sleep. Objectives: We aimed to determine the effects of the combination (...) of a norepinephrine reuptake inhibitor (atomoxetine) and an antimuscarinic (oxybutynin) on OSA severity (apnea-hypopnea index [AHI]; primary outcome) and genioglossus responsiveness (secondary outcome) in people with OSA. Methods: A total of 20 people completed a randomized, placebo-controlled, double-blind, crossover trial comparing 1 night of 80 mg atomoxetine plus 5 mg oxybutynin (ato-oxy) to placebo administered before sleep. The AHI and genioglossus muscle responsiveness to negative esophageal pressure

2019 EvidenceUpdates

30. Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial (Abstract)

-110), a selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects, for the treatment of excessive sleepiness in participants with obstructive sleep apnea with current or prior sleep apnea treatment. Methods: This was a double-blind, randomized, placebo-controlled, parallel-group, 12-week trial comparing solriamfetol, 37.5, 75, 150, and 300 mg, with placebo. Measurements and Main Results: Of 476 randomized participants, 459 were included in the prespecified (...) participants; five participants experienced serious adverse events (two [1.7%] placebo, three [0.8%] solriamfetol); none were deemed related to study drug. The most common adverse events with solriamfetol were headache (10.1%), nausea (7.9%), decreased appetite (7.6%), anxiety (7.0%), and nasopharyngitis (5.1%). Conclusions: Solriamfetol significantly increased wakefulness and reduced sleepiness in participants with obstructive sleep apnea and excessive sleepiness; most adverse events were mild or moderate

2019 EvidenceUpdates

31. Belsomra (Suvorexant) - for the treatment of insomnia

Belsomra (Suvorexant) - for the treatment of insomnia Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1

2019 Health Canada - Drug and Health Product Register

32. Insomnia

process. 3 Insomnia Assessment and Diagnosis Insomnia is a diagnosis of exclusion. Patients who report difficulty initiating sleep, difficulty maintaining sleep, waking too early, or experiencing non-restorative sleep should be assessed to evaluate for: • Comorbid medical conditions (e.g., pulmonary disease, heart failure, chronic pain) • Comorbid psychiatric disorders (e.g., depression, anxiety, post-traumatic stress disorder, substance abuse) • Other sleep disorders (e.g., obstructive sleep apnea (...) , restless legs syndrome, circadian rhythm sleep-wake disorders) It is important to screen the patient for depression, substance use, and alcohol use, as about 1 in 3 patients reporting insomnia have co-occurring psychiatric illness (typically depression or anxiety) and 1 in 6 have alcohol- or drug-induced sleep problems. It is also important to review the patient’s current medications. Table 1 lists medications that may interfere with sleep. • Medication effects on sleep are complex. Medications can

2019 Kaiser Permanente Clinical Guidelines

33. Association of Unrecognized Obstructive Sleep Apnea With Postoperative Cardiovascular Events in Patients Undergoing Major Noncardiac Surgery. Full Text available with Trip Pro

Association of Unrecognized Obstructive Sleep Apnea With Postoperative Cardiovascular Events in Patients Undergoing Major Noncardiac Surgery. Unrecognized obstructive sleep apnea increases cardiovascular risks in the general population, but whether obstructive sleep apnea poses a similar risk in the perioperative period remains uncertain.To determine the association between obstructive sleep apnea and 30-day risk of cardiovascular complications after major noncardiac surgery.Prospective cohort (...) sleep monitoring.The primary outcome was a composite of myocardial injury, cardiac death, heart failure, thromboembolism, atrial fibrillation, and stroke within 30 days of surgery. Proportional-hazards analysis was used to determine the association between obstructive sleep apnea and postoperative cardiovascular complications.Among a total of 1364 patients recruited for the study, 1218 patients (mean age, 67 [SD, 9] years; 40.2% women) were included in the analyses. At 30 days after surgery, rates

2019 JAMA

34. Solriamfetol (Sunosi) - To treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea

Solriamfetol (Sunosi) - To treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea Drug Approval Package: Sunosi U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Sunosi Company: Jazz Pharmaceuticals Ireland Limited Application Number: 211230 Approval Date: 03/20/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF

2019 FDA - Drug Approval Package

35. Indigenous Food Safety and Security: Community Adaptations in the Wake of Climate Pressures

Indigenous Food Safety and Security: Community Adaptations in the Wake of Climate Pressures INDIGENOUS FOOD SAFETY AND SECURITY: COMMUNITY ADAPTATIONS IN THE WAKE OF CLIMATE PRESSURES FEBRUARY 2019 Prepared by: Leela Steiner, National Collaborating Centre for Environmental Health Casey Neathway, First Nations Health AuthorityNational Collaborating Centre for Environmental Health 1 INTRODUCTION Indigenous people have long relied on traditional foods, as they are nutritionally, culturally (...) public health risks while at the same time supporting community efforts to improve food safety in the wake of their adaptation efforts to address climatic pressures. This review presents evidence on six unique food safety issues, based on adaptation measures taken or planned to be taken to help ensure food security: 1) smokehouse construction considerations; 2) gardening and the use of tires as planters; 3) greywater use in crop irrigation; 4) traditional preservation techniques (specifically sun

2019 National Collaborating Centre for Environmental Health

36. Positional therapy for obstructive sleep apnoea. (Abstract)

Positional therapy for obstructive sleep apnoea. The modalities of therapy for obstructive sleep apnoea (OSA) include behavioural and lifestyle modifications, positional therapy, oral appliances, surgery and continuous positive airway pressure therapy (CPAP). Though CPAP has proven efficacy in treating OSA, adherence with CPAP therapy is suboptimal. Positional therapy (to keep people sleeping on their side) is less invasive and therefore expected to have better adherence. This review considered (...) therapy. Two studies showed that CPAP produced a greater reduction in Apnoea-Hypopnoea Index (AHI) with a mean difference (MD) of 6.4 events per hour (95% CI 3.00 to 9.79; low-certainty evidence) compared to positional therapy. Subjective adherence, evaluated in one study, was found to be significantly greater with positional therapy (MD 2.5 hours per night, 95% CI 1.41 to 3.59; moderate-certainty evidence).In terms of secondary outcomes, one study each reported quality-of-life indices and quality

2019 Cochrane

37. Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure

to treat adult patients with sleep-related breathing disorders. Sleep . 2006;29(3):375–380. [ ] 2 Kushida CA, Chediak A, Berry RB, et al. Clinical guidelines for the manual titration of positive airway pressure in patients with obstructive sleep apnea. J Clin Sleep (...) , Minnesota; 4 McGill University Health Centre, Montreal, Quebec, Canada; 5 University of Pittsburgh, Pittsburgh, Pennsylvania; 6 American Academy of Sleep Medicine, Darien, Illinois ABSTRACT Introduction: This guideline establishes clinical practice recommendations for positive airway pressure (PAP) treatment of obstructive sleep apnea (OSA) in adults and is intended for use in conjunction with other American Academy of Sleep Medicine (AASM) guidelines in the evaluation and treatment of sleep-disordered

2019 American Academy of Sleep Medicine

38. Proof of Concept for an Adaptive Treatment Strategy to Prevent Failures in Internet-Delivered CBT: A Single-Blind Randomized Clinical Trial With Insomnia Patients (Abstract)

Proof of Concept for an Adaptive Treatment Strategy to Prevent Failures in Internet-Delivered CBT: A Single-Blind Randomized Clinical Trial With Insomnia Patients This study aimed to demonstrate proof of concept for an adaptive treatment strategy in Internet-delivered cognitive-behavioral therapy (ICBT), where risk of treatment failure is assessed early in treatment and treatment for at-risk patients is adapted to prevent treatment failure.A semiautomated algorithm assessed risk of treatment (...) failure early in treatment in 251 patients undergoing ICBT for insomnia with therapist guidance. At-risk patients were randomly assigned to continue standard ICBT or to receive adapted ICBT. The primary outcome was self-rated insomnia symptoms using the Insomnia Severity Index in a linear mixed-effects model. The main secondary outcome was treatment failure (having neither responded nor remitted at the posttreatment assessment).A total of 102 patients were classified as at risk and randomly assigned

2019 EvidenceUpdates

39. Effects of short-term continuous positive airway pressure withdrawal on cerebral vascular reactivity measured by blood oxygen level-dependent magnetic resonance imaging in obstructive sleep apnoea: a randomised controlled trial (Abstract)

(CPAP) withdrawal on CVR.41 OSA patients (88% male, mean age 57±10 years) were randomised to either subtherapeutic or continuation of therapeutic CPAP. At baseline and after 2 weeks, patients underwent a sleep study and magnetic resonance imaging (MRI). CVR was estimated by quantifying the blood oxygen level-dependent (BOLD) MRI response to breathing stimuli.OSA did recur in the subtherapeutic CPAP group (mean treatment effect apnoea-hypopnoea index +38.0 events·h-1, 95% CI 24.2-52.0; p<0.001 (...) Effects of short-term continuous positive airway pressure withdrawal on cerebral vascular reactivity measured by blood oxygen level-dependent magnetic resonance imaging in obstructive sleep apnoea: a randomised controlled trial Impaired cerebral vascular reactivity (CVR) increases long-term stroke risk. Obstructive sleep apnoea (OSA) is associated with peripheral vascular dysfunction and vascular events. The aim of this trial was to evaluate the effect of continuous positive airway pressure

2019 EvidenceUpdates

40. Does CPAP ameliorate the risk of cardiovascular events in patients with obstructive sleep apnea?

with sleep-disordered breathing: The Sleep Heart Health Study. Am J Respir Crit Care Med 2006; 173:910. Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation 2010; 122:352. Yumino D, Tsurumi Y, Takagi A, et al. Impact of obstructive sleep apnea on clinical and angiographic outcomes following percutaneous coronary intervention in patients with acute coronary syndrome. Am J (...) , Vgontzas AN, Lin HM, et al. Prevalence of sleep-disordered breathing in women: effects of gender. Am J Respir Crit Care Med 2001;163:608-613. Basner RC. Continuous positive airway pressure for obstructive sleep apnea. N Engl J Med . 2007;356:1751–8. doi: 10.1056/NEJMct066953. White DP. Pathogenesis of obstructive and central sleep apnea. Am J Respir Crit Care Med 2005;172:1363-1370. Loube DI, Gay PC, Strohl KP, Pack AI, White DP, Collop NA. Indications for positive airway pressure treatment of adult

2019 Clinical Correlations